Example: Heart Attack

Clinical Trials on Neisseria Meningitidis Infection

Total 133 results

NCT02141516

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Conditions: Meningococcal Disease
NCT01640652

Unknown status

MenPF-1 - A New Vaccine Against Meningococcal Disease

Conditions: Serogroup B Meningococcal Disease
NCT00601731

Completed

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Conditions: Meningococcal Disease
NCT00433914

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of Meningococcal B Recombinant Vaccine, When Administered to Healthy Infants

Conditions: Meningococcal Disease
NCT00297817

Completed

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Conditions: Meningococcal Disease
NCT01994629

Completed

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

Conditions: Meningococcal Disease
NCT00560313

Completed

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Conditions: Meningococcal Disease
NCT01303211

Withdrawn

A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger

Conditions: Meningococcal Disease
NCT00488683

Completed

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Conditions: Meningococcal Disease
NCT02140762

Completed

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Conditions: Meningococcal Disease
NCT01139021

Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

Conditions: Meningococcal Disease
NCT00847145

Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

Conditions: Meningococcal Disease
NCT01911221

Completed

A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.

Conditions: Prevention of the Meningococcal Disease
NCT00661713

Completed

Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine Administered to Healthy Adolescents According to Different Vaccination Schedules

Conditions: Meningococcal Disease
NCT01027351

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of Booster Doses of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received One or Four Doses of the Same Vaccine

Conditions: Meningococcal Disease
NCT01026974

Completed

Extension Study Evaluating Antibody Persistence and Safety, Tolerability and Immunogenicity of a Booster Dose of Novartis rMenB±OMV NZ Vaccine in Healthy UK Children Who Previously Received Three Doses of the Same Vaccine

Conditions: Meningococcal Disease
NCT01133834

Completed

Correlation Between Cytokines and the Severity of Meningococcal Disease

Conditions: Meningococcemia
NCT03089086

Completed

South Australian Meningococcal B Vaccine Herd Immunity Study

Conditions: Meningococcal Disease
NCT01705379

Withdrawn

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older

Conditions: Meningococcal Disease
NCT02811120

Completed

PRIME Follow up - Quadri Meningo Vacinees

Conditions: Meningococcal Disease
NCT01766206

Completed

Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea

Conditions: Meningococcal Disease
NCT02285777

Completed

Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Conditions: Meningococcal Disease
NCT01992536

Completed

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Conditions: Meningococcal Disease
NCT01973218

Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Conditions: Meningococcal Disease
NCT01823536

Completed

Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose

Conditions: Meningococcal Disease